Toril Holien

Summary

Affiliation: Norwegian University of Science and Technology
Country: Norway

Publications

  1. doi The role of bone morphogenetic proteins in myeloma cell survival
    Toril Holien
    KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU, Faculty of Medicine, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway Electronic address
    Cytokine Growth Factor Rev 25:343-50. 2014
  2. pmc Oncogene addiction to c-MYC in myeloma cells
    Toril Holien
    KG Jebsen Center for Myeloma Research and Department of Cancer Research an Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget 3:739-40. 2012
  3. ncbi Addiction to c-MYC in multiple myeloma
    Toril Holien
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 120:2450-3. 2012
  4. doi HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase
    Torstein Baade Rø
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Hematol 41:646-55. 2013
  5. doi Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate
    Toril Holien
    Department of Cancer Research and Molecular Medicine, KG Jebsen Center for Myeloma Research, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 91:339-46. 2013
  6. pmc Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells
    Rebekka Müller
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    PLoS ONE 8:e70430. 2013
  7. pmc c-Met signaling promotes IL-6-induced myeloma cell proliferation
    Håkon Hov
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 82:277-87. 2009
  8. pmc MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
    Toril Holien
    K G Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget 6:22698-705. 2015
  9. doi A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells
    Kristine Misund
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Biomol Screen 18:637-46. 2013
  10. doi CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis
    Nikolai N Nørgaard
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Immunol 185:3131-9. 2010

Collaborators

Detail Information

Publications13

  1. doi The role of bone morphogenetic proteins in myeloma cell survival
    Toril Holien
    KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU, Faculty of Medicine, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway Electronic address
    Cytokine Growth Factor Rev 25:343-50. 2014
    ..Our review highlights and discusses the current knowledge on BMP signaling in myeloma. ..
  2. pmc Oncogene addiction to c-MYC in myeloma cells
    Toril Holien
    KG Jebsen Center for Myeloma Research and Department of Cancer Research an Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget 3:739-40. 2012
    ..c-MYC is in many cases central to cancer cell survival and due to its functional nonredundancy, it may not be easily replaced by alternative signaling mechanisms...
  3. ncbi Addiction to c-MYC in multiple myeloma
    Toril Holien
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 120:2450-3. 2012
    ..Our results provide further evidence that myeloma cells are addicted to c-MYC activity and that c-MYC is a promising therapeutic target in multiple myeloma...
  4. doi HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase
    Torstein Baade Rø
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Hematol 41:646-55. 2013
    ..These findings are likely to be of clinical relevance because multiple myeloma cells are located in an environment containing HGF and IGF-1 and are exposed to an SDF-1α gradient between the bone marrow and peripheral blood. ..
  5. doi Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate
    Toril Holien
    Department of Cancer Research and Molecular Medicine, KG Jebsen Center for Myeloma Research, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 91:339-46. 2013
    ..The widely used malaria drug artesunate has been reported to have antitumor activity, and we aimed to test the effects of artesunate on a panel of myeloma and lymphoma cells...
  6. pmc Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells
    Rebekka Müller
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    PLoS ONE 8:e70430. 2013
    ..In a xenograft mouse model, ATX-101 was well tolerated and increased the anti-tumor activity of melphalan. Therefore, targeting PCNA by ATX-101 may be a novel strategy in multiple myeloma treatment. ..
  7. pmc c-Met signaling promotes IL-6-induced myeloma cell proliferation
    Håkon Hov
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 82:277-87. 2009
    ..We therefore wanted to investigate if HGF could influence the effects of interleukin (IL)-6...
  8. pmc MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
    Toril Holien
    K G Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget 6:22698-705. 2015
    ..Sensitivity of myeloma cell lines to the MYC inhibitor 10058-F4 correlated with MYC expression, supporting that the activity of 10058-F4 was through specific inhibition of MYC. ..
  9. doi A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells
    Kristine Misund
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Biomol Screen 18:637-46. 2013
    ..Stromal cell-induced protection against common myeloma drugs is also observed with this method. ..
  10. doi CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis
    Nikolai N Nørgaard
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Immunol 185:3131-9. 2010
    ..In conclusion, our results demonstrate that PTO-CpG-ODN inhibits BMP-signaling, and thus might provoke unwanted TLR9-independent side effects in patients...
  11. pmc Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
    Oddrun Elise Olsen
    K G Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N 7491, Trondheim, Norway
    Cell Commun Signal 13:27. 2015
    ..Activin A is also elevated in myeloma patients with advanced disease and is involved in myeloma bone disease...
  12. pmc Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
    Unn Merete Fagerli
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
    Blood 111:806-15. 2008
    ..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells...